March 05
12:00 pm - 1:00 pm EST

LOCAL TIME

3 things every life sciences company should know before leveraging AI to generate real-world evidence

AI (Artificial Intelligence) seems to be the buzz word on everyone’s tongue when they’re talking about analyzing healthcare data. But with everyone claiming to use AI, how do you know what to look for, what questions to ask, and what AI models to trust when generating real-world evidence (RWE)? RWE has become a key tool for life sciences companies to better understand treatment patterns and patient outcomes, meet regulatory requirements, or even identify patients for clinical trials. This webinar will be a discussion that explores the intersection of applying AI to RWD to generate RWE and provide valuable insights that can help inform your next research project.

In this webinar, experts from Verana Health and Datavant will:
  • Share 3 key things to be aware of before engaging in a project that applies AI to RWD for analysis
  • Provide examples of the impact AI is already having on RWE
  • Highlight case studies that showcase successful applications of AI approaches to generate quality RWE

register now
register for the webinar

No cost to register, subject to confirmation.

By registering for this event, you accept that you may receive direct communication from the sponsor(s) and email marketing about Endpoints News webinars.

If you are experiencing problems with your registration, please try the Zoom registration page.

Lawrence Whittle

Lawrence Whittle

President, Verana Health

Lawrence Whittle is president of Verana Health and is responsible for driving market positioning, sales, partnerships and overall customer success for both Life Sciences and Clinical communities. This remit spans a multitude of stakeholders to elevate awareness and value across the care continuum. Lawrence has 25+ years’ experience as a senior executive within technologies companies spanning different industries, including Data Analytics and Life Sciences. His deep expertise in commercialization and customer success has covered elevating company positioning, driving sustainable customer value through deep in-market partnerships, and nurturing strong collaborations across all key functions of the business.

Vera Mucaj

Vera Mucaj

Chief Scientific Officer, Datavant

Vera is the Chief Scientific Officer at Datavant, where she leads cross-functional teams dedicated to advancing technology and identifying applications for connected health data in research. As a technology leader, Vera has successfully guided the development and widespread adoption of products supporting healthcare data connectivity through Privacy - Preserving Record Linkages. Her subject-matter expertise includes the technical and use case considerations for linking clinical trial data to real-world data, and the creation of large-scale real-world data research databases in both the public and private sectors. Vera is a research scientist by training, and holds a BA in Biochemistry from Harvard College, and a PhD in Cell and Molecular Biology from the University of Pennsylvania Perelman School of Medicine. She has authored multiple peer-reviewed scientific papers in cancer research. Prior to joining Datavant, Vera worked at McKinsey & Company, where she supported pharmaceutical clients on growth strategy, business development, and M&A.

Aracelis Torres

Aracelis Torres

Senior Vice President of Data & Science, Verana Health

Aracelis Torres, PhD, MPH, is Senior Vice President of Data & Science, where she oversees the Quantitative Sciences team working on rigorous methodology to generate sound scientific evidence from real-world data as well as the commercial services and operations team that manage client deliverables. Dr. Torres is an epidemiologist with more than 15 years of academic and industry experience. Prior to joining Verana Health, she was a Director of Quantitative Sciences at Flatiron Health, where her work focused on translation of real-world oncology data to generate evidence. While at Flatiron Health, she led efforts related to the development of real-world endpoints, novel study designs, and prospective evidence generation while also serving as the Quantitative Sciences lead for the organization’s broader research collaboration with the Food and Drug Administration. She is also currently an Adjunct Professor at Columbia University Graduate School of Arts and Sciences, where she teaches a course on large-scale data processing and analysis. Dr. Torres received a PhD in Cancer Epidemiology from Johns Hopkins Bloomberg School of Public Health, an MPH in Chronic Disease Epidemiology from Yale University’s School of Public Health, and a BS in Molecular, Cellular, and Developmental Biology from Yale University.

Kari Abitbol
moderator

Kari Abitbol

Head of Webinars & Client Success, Endpoints News

As head of the client success team at Endpoints News, Kari oversees campaign delivery and strategy for all advertising and client-directed webinars. She brings nearly 20 years of diverse experience across strategic communications, content development and operational leadership.